Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Verastem Inc VSTM

Healthcare Biotechnology
Verastem, Inc. is a late-stage development biopharmaceutical company. The Company's pipeline is focused on anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) inhibition and focal adhesion kinase (FAK) inhibition. The Company’s advanced... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:VSTM)

Verastem Oncology Announces Appointment of John Hayslip, M.D., to Chief Medical Officer

Business Wire 5 days ago

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire April 4, 2024

Global Patient Survey Results Reveal Significant Negative Impact on Social, Emotional and Mental Well-Being for People Living with Low-Grade Serous Ovarian Cancer

Business Wire March 18, 2024

Verastem Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates

Business Wire March 14, 2024

Verastem Oncology Announces Multiple Oral Presentations at SGO 2024 Annual Meeting on Women's Cancer that Highlight Advances in Low-Grade Serous Ovarian Cancer Research and Reinforce Commitment to Addressing Urgent Unmet Needs

Business Wire March 11, 2024

Verastem Oncology Receives Orphan Drug Designation from FDA for Avutometinib Alone or in Combination With Defactinib in Recurrent Low-Grade Serous Ovarian Cancer

Business Wire March 5, 2024

Verastem Oncology Announces Preclinical Presentations for New Oral G12D Inhibitor and for Avutometinib and Defactinib Combination as a Backbone of Therapy for RAS/MAPK Driven Cancers at AACR Annual Meeting 2024

Business Wire March 5, 2024

Verastem Oncology Outlines Key 2024 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib and Defactinib and Broader Pipeline in RAS Pathway-Driven Cancers

Business Wire January 29, 2024

Verastem Oncology Granted Fast Track Designation for Combination of Avutometinib and Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer (NSCLC)

Business Wire January 18, 2024
View More News ››

Opinion & Analysis (NDAQ:VSTM)

Seven biotech names on the upswing: 2016 small-cap biotech watchlist update

The Life Sciences Report March 11, 2016
View More Opinion ››

Bullboard Posts (NDAQ:VSTM)

RE:VSTM ..... pays yo money and yo takes

I failed to mention....lots of stock O/S
Iseneschal - May 26, 2023

VSTM ..... pays yo money and yo takes

yo chances Beating my expectations lotsa cash in the Kitty but lots of debt and no Rev...go figure
Iseneschal - May 26, 2023

RE:Statistically we are approved!

There are lies, damned lies, and then there are statistics.  Maliciously contrived lies.
DryBones - November 8, 2019

Predicted the Fall

If you were using leading indicators as a part of your strategy, then you were away of VSTM's drop almost 1 week ago.  For the...
BluSignals - September 25, 2018

Statistically we are approved!

Statistics do NOT lie!
FDAMaster - September 14, 2018

RE:Down

I sold this a few days back.  But I am looking for re entry.  I will wait a bit and see where the market takes it.   But I...
mevani - September 6, 2018
View more Bullboard ››

Mandalay Resources Corp.

Mandalay Resources Corp.

Mandalay Resources Corporation is a Canada-based natural resource company with producing assets in Australia (Costerfield ...
View More »